Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Fitch Ratings Agency to BB+ from BB, with a stable outlook. The upgrade follows a recent rating improvement from Moody's and reflects Teva's successful debt reduction efforts and improved financial flexibility. Fitch's report highlights expected revenue growth from key products AUSTEDO and AJOVY, along with the company's promising biosimilar pipeline. The agency also noted that Teva's focus on optimizing external spend, resource allocation, and organizational modernization is anticipated to boost operating margins.
Teva Pharmaceuticals (TEVA) ha ottenuto un miglioramento del rating creditizio da parte di Fitch Ratings Agency, che lo ha portato a BB+ da BB, con outlook stabile. L'upgrade segue un recente miglioramento del rating da Moody's e riflette i successi di Teva nella riduzione del debito e nel miglioramento della flessibilità finanziaria. Il rapporto di Fitch evidenzia una crescita prevista dei ricavi dai prodotti chiave AUSTEDO e AJOVY, insieme a una promettente pipeline di biosimilari. L'agenzia ha inoltre sottolineato che l'attenzione di Teva all'ottimizzazione della spesa esterna, all'allocazione delle risorse e alla modernizzazione organizzativa dovrebbe favorire un aumento dei margini operativi.
Teva Pharmaceuticals (TEVA) ha recibido una mejora en su calificación crediticia por parte de Fitch Ratings Agency, pasando a BB+ desde BB, con perspectiva estable. La mejora sigue a una reciente actualización de Moody's y refleja los esfuerzos exitosos de Teva para reducir su deuda y mejorar su flexibilidad financiera. El informe de Fitch destaca un crecimiento esperado en los ingresos de los productos clave AUSTEDO y AJOVY, junto con la prometedora cartera de biosimilares de la compañía. La agencia también señaló que el enfoque de Teva en optimizar el gasto externo, la asignación de recursos y la modernización organizativa se anticipa que impulsará los márgenes operativos.
테바 제약사(TEVA)는 Fitch Ratings Agency로부터 신용 등급이 BB에서 BB+로 상향 조정되었으며, 전망은 안정적입니다. 이번 등급 상향은 Moody's의 최근 등급 개선에 이어 이루어진 것으로, 테바의 성공적인 부채 감축 노력과 재무 유연성 향상을 반영합니다. Fitch 보고서는 핵심 제품인 AUSTEDO와 AJOVY의 매출 성장 전망과 함께 회사의 유망한 바이오시밀러 파이프라인을 강조했습니다. 또한, Fitch는 테바가 외부 지출 최적화, 자원 배분, 조직 현대화에 집중함으로써 영업 이익률이 향상될 것으로 기대된다고 언급했습니다.
Teva Pharmaceuticals (TEVA) a reçu une amélioration de sa note de crédit par l'agence Fitch Ratings, passant de BB à BB+ avec une perspective stable. Cette amélioration fait suite à une récente revalorisation par Moody's et reflète les efforts réussis de Teva pour réduire sa dette et améliorer sa flexibilité financière. Le rapport de Fitch met en avant la croissance attendue des revenus des produits clés AUSTEDO et AJOVY, ainsi que le pipeline prometteur de biosimilaires de l'entreprise. L'agence a également noté que l'accent mis par Teva sur l'optimisation des dépenses externes, l'allocation des ressources et la modernisation organisationnelle devrait favoriser une augmentation des marges opérationnelles.
Teva Pharmaceuticals (TEVA) hat von der Ratingagentur Fitch eine Heraufstufung der Kreditwürdigkeit von BB auf BB+ mit stabilem Ausblick erhalten. Die Heraufstufung folgt auf eine kürzliche Verbesserung des Ratings durch Moody's und spiegelt Tevas erfolgreiche Schuldenreduzierung und verbesserte finanzielle Flexibilität wider. Der Bericht von Fitch hebt das erwartete Umsatzwachstum der wichtigsten Produkte AUSTEDO und AJOVY sowie die vielversprechende Biosimilar-Pipeline des Unternehmens hervor. Die Agentur stellte außerdem fest, dass Tevas Fokus auf die Optimierung externer Ausgaben, Ressourcenallokation und organisatorische Modernisierung voraussichtlich die operativen Margen steigern wird.
- Credit rating upgrade to BB+ from BB by Fitch Ratings
- Second consecutive upgrade from Fitch and recent upgrade from Moody's
- Successful debt reduction and improved financial flexibility
- Expected revenue growth from AUSTEDO and AJOVY products
- Potential for higher operating margins through optimization initiatives
- None.
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB.
Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline. In addition, Fitch mentions that Teva's focus on optimizing external spend, prioritizing resource allocation, and modernizing its organization is expected to lead to higher operating margins.
“We are proud to receive a second consecutive upgrade from Fitch within several months, especially coming on the heels of Moody’s upgrade last Friday. This recognition reflects the strength of our financial discipline and the unwavering commitment of our teams. It’s a powerful endorsement of our Pivot to Growth strategy and a clear signal of confidence in our future,” said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com |
FAQ
What is TEVA's new credit rating from Fitch Ratings?
Why did Fitch upgrade TEVA's credit rating in 2025?
How many credit rating upgrades has TEVA received recently?
What products are driving TEVA's revenue growth according to Fitch?
How is TEVA planning to improve its operating margins?
